An unusual approach to funding spinal muscular atrophy yields promise.

At the Cerebral Fluid Center at Johns Hopkins, neurosurgeons, neurologists, pain experts and therapists treat patients in tandem.

Studies suggest that treatment with the amino acid offers a novel signaling pathway that differs from those targeted by anti-seizure medications.

Tools approved for use just three years ago could make the difference for patients.